Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Non-Small-Cell Lung Cancer
DRUG: Vebreltinib|DRUG: PLB1004
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])., In phase Ib，Incidence of Treatment-Emergent Adverse Events (TEAEs),, 3 years|Incidence of dose-limiting toxicities (DLT) as defined in the protocol., In phase Ib，Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol, 28 days|Overall Response Rate (ORR）, In phase II,ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1., 3 years
Pharmacokinetics of Vebreltinib and PLB1004 : Area under the concentration time curve (AUC), In phase Ib，Measurement of PK parameters: Area under the concentration time curve (AUC), From date of first dose up until 28 days post last dose|Pharmacokinetics of Vebreltinib and PLB1004: Maximum plasma concentration of the study drug (C-max), In phase Ib，Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max), From date of first dose up until 28 days post last dose|Pharmacokinetics of Vebreltinib and PLB1004: Time to maximum plasma concentration of the study drug (T-max), In phase Ib，Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max), From date of first dose up until 28 days post last dose|Incidence of Treatment-Emergent Adverse Events, In phase II，Incidence of Treatment-Emergent Adverse Events (TEAEs),A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug., 3 years
Open label, multicenter Phase Ib/II clinical study to evaluate the safety, efficacy, and pharmacokinetics of Vebreltinib in combination with PLB1004 in patients with locally advanced or metastatic non-small cell lung cancer with MET overexpression or MET amplification following EGFR-TKI treatment failure.